ABSCI CORP Foreign Income Tax Expense (Benefit), Continuing Operations
ABSCI CORP (ABSI) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $239.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-24
- ABSCI CORP foreign income tax expense (benefit), continuing operations for fiscal 2025 was $239.00K, a 79.70% increase from fiscal 2024.
- ABSCI CORP foreign income tax expense (benefit), continuing operations for fiscal 2024 was $133.00K.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | $239.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $133.00K 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |